NTD ConnectOR ~ Advanced search

Human Diagnostics Tool Development (CAA diagnostic tool)

POC/CCA screening/mapping tool initial Studies

Screening Tool POC/CCA: PCR comparative studies

POC/CCA tool ongoing studies: Use of testing standards; reader differences; ‘Trace’ result analyses

Cost Studies in SCORE Gaining and Sustaining

Mapping of schistosomiasis (Sm)

Develop genetic markers for S. haematobium

Schistosome Population Genetics in Gaining Control Studies in Niger (Sh) and Tanzania (Sm)

Part of gaining control studies

Gaining Control: >25% Prevalence MDA strategies; and subtle morbidity of Cohort; Population genetics, and snail monitoring

Sustaining / Gaining Control with Single versus Double Treatment; and Population genetics, snail monitoring

MDA strategies: Sustaining control at 10 – 24% prevalence

(1) Is it possible to eliminate schistosomiasis as a public health problem on Unguja in three years and to interrupt transmission in five years? (2) Is it possible to control schistosomiasis throughout Pemba (prevalence <10%) in three years and to eliminate it as a public health problem in five years? (3) What are the costs, successful strategies, barriers, etc. associated with three different interventions (MDA, vector control, and behavior change)?

Randomized clinical trail comparing treatment with Albendazole and Ivermectin to Ivermectin alone for Onchocerciasis.

Randomized Clinical Trial of Albendazole vs Ivermectin+Albendazole for lymphatic filariasis treatment and elimination.

Randomized Clinical Trial comparing triple triple therapy of DEC/Alb/Iver vs. DEC/Alb alone

Comparison of 2X vs. 1X per year MDA on Brugia with MDA of DEC/Alb , plus STH evaluation

Community MDA with 2X Alb alone for W. bancrofti in areas co-endemic for L. loa, plus STH evaluation

Binax Now Filariasis Test vs. Alere Filariasis Test Strip Comparison

Comparison of 2X vs. 1X per year MDA on W. bancrofti with MDA of IVM/Alb, plus STH evaluation (and Schistosoma in Foya only)

Comparison of 2X vs. 1X per year MDA, W. bancrofti with MDA of DEC/Alb, plus STH evaluation